GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » 3-Year Dividend Growth Rate

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) 3-Year Dividend Growth Rate : 0.00% (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals 3-Year Dividend Growth Rate?

Great Novel Therapeutics Biotech & Medicals's Dividends per Share for the six months ended in Jun. 2024 was NT$0.00.

The historical rank and industry rank for Great Novel Therapeutics Biotech & Medicals's 3-Year Dividend Growth Rate or its related term are showing as below:

ROCO:7427's 3-Year Dividend Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 13.2
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Great Novel Therapeutics Biotech & Medicals's Dividend Payout Ratio for the six months ended in Jun. 2024 was 0.00. As of today, Great Novel Therapeutics Biotech & Medicals's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Great Novel Therapeutics Biotech & Medicals's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Great Novel Therapeutics Biotech & Medicals's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Great Novel Therapeutics Biotech & Medicals's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Great Novel Therapeutics Biotech & Medicals's 3-Year Dividend Growth Rate falls into.



Great Novel Therapeutics Biotech & Medicals 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.


Great Novel Therapeutics Biotech & Medicals  (ROCO:7427) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Great Novel Therapeutics Biotech & Medicals's Dividend Payout Ratio for the quarter that ended in Jun. 2024 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Jun. 2024 )/ EPS without NRI (Q: Jun. 2024 )
=0/ -1.6
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Great Novel Therapeutics Biotech & Medicals 3-Year Dividend Growth Rate Related Terms>


Great Novel Therapeutics Biotech & Medicals Business Description

Traded in Other Exchanges
N/A
Address
No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals Headlines

No Headlines